-

AceLink Therapeutics to present two posters on Fabry Disease and Gaucher Disease at 2023 WORLD Symposium

NEWARK, Calif.--(BUSINESS WIRE)--AceLink Therapeutics, Inc. (AceLink), an innovative biopharmaceutical company developing transformative therapies for genetic diseases, today announced that the company will present two abstracts featuring the development of AL01211 to treat Fabry disease and AL00804 to treat Gaucher disease and other neuronopathic glycosphingolipid storage diseases at the 19th Annual World Symposium Conference, being held in Orlando, Florida, from February 22-26, 2023.

Details of the abstracts are as follows:

Abstract Title: Development of AL00804, a novel brain penetrant glucosylceramide synthase inhibitor, to treat Gaucher disease and other neuronopathic glycosphingolipid storage diseases
Authors: Michael Babcock, Ying Feng, Benjamin Liou, Venette Fannin, Yi Lin, Jerry Shen, Ying Sun
Session Title: Basic Science – Poster Session III
Session Date & Time: Thursday, February 23, 3:00 PM - 4:00 PM ET
Abstract Number: LB-07
Location: Hilton Orlando, Kiosk 26-B

Abstract Title: Development of AL01211, an oral, non-brain penetrant glucosylceramide synthase inhibitor (GCSi), to treat Fabry disease
Authors: Michael Babcock, Jianhong Zheng, Li Li, Jessica Gail Shurr, Marvin Garovoy, Jerry Shen
Session Title: Translational Research – Poster Session IV
Session Date & Time: Thursday, February 23, 4:00 PM - 5:00 PM ET
Abstract Number: LB-08
Location: Hilton Orlando, Kiosk 8-A

About AL01211

AL01211 is a proprietary, non-brain penetrant GCS inhibitor with excellent potency (single-digit nanomolar IC50), great selectivity, and other favorable drug properties that support once-daily oral administration. AL01211 offers a much-needed oral small molecule therapy as an alternative to current therapies for Fabry disease that require frequent intravenous infusions. Phase II clinical studies of AL01211 in patients with Fabry disease are planned to start in 2023.

About AL00804

AL00804 is a highly brain penetrant GCS inhibitor being developed for the treatment of neuropathic glycolipid storage diseases including Gaucher disease, GM2 gangliosidosis (Tay-Sach and Sandhoff disease), GM1 gangliosidosis, and possibly certain genetic forms of Parkinson’s disease.

About GCS inhibitor

GCS (glucosylceramide synthase) catalyzes the first step in the synthesis of glycosphingolipids, a group of bioactive molecules that play important roles in various cellular processes and diseases. GCS inhibitors reduce the production of glycosphingolipids, thereby exerting beneficial effects to diseases such as Fabry disease and Gaucher disease, which are caused by the accumulation of these lipids.

About AceLink Therapeutics, Inc.

Founded in 2018, AceLink Therapeutics is an innovative biopharma startup focusing on developing safe and effective medicines to address genetic diseases with high unmet needs. The company’s initial focus is to develop novel therapeutics for Fabry disease. For more information, please visit www.acelinktherapeutics.com.

Contacts

Kiki Patel, PharmD
Gilmartin Group, Principal
Kiki@gilmartinir.com

AceLink Therapeutics, Inc.


Release Versions

Contacts

Kiki Patel, PharmD
Gilmartin Group, Principal
Kiki@gilmartinir.com

More News From AceLink Therapeutics, Inc.

AceLink Therapeutics Announces Publication of Phase 1 Clinical Trial Data Evaluating AL01211 in Healthy Volunteers

NEWARK, Calif.--(BUSINESS WIRE)--AceLink Therapeutics, Inc., a clinical-stage biopharmaceutical company developing next generation oral substrate reduction therapies (SRTs), today announced that the findings from their Phase 1 study of AL01211 in healthy volunteers have been published in the peer-reviewed journal Clinical Pharmacology in Drug Development, a journal of the American College of Clinical Pharmacy. AL01211 is a potent, oral, glucosylceramide synthase (GCS) inhibitor being developed...

AceLink Announces First Patient Dosed in Phase 2 Trial of AL01211 in Fabry Disease

NEWARK, Calif.--(BUSINESS WIRE)--AceLink Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the next generation of oral substrate reduction therapies (SRTs), announced today that the first patient has been dosed with AL01211 in its Phase 2 trial in China in patients with Fabry disease. AL01211 is a novel, oral, non-brain penetrant glucosylceramide synthase (GCS) inhibitor being developed to treat glycosphingolipid storage diseases, including Fabry Disease and Type 1 Gauch...

AceLink Opens First Clinical Site in China for Phase 2 Study in Fabry Disease

NEWARK, Calif.--(BUSINESS WIRE)--AceLink Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced the opening of the first clinical trial site in China for its Phase 2, open‑label study of the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary measures of physiological efficacy of AL01211 in males with classic Fabry disease who have not been previously treated with other Fabry disease therapies. AceLink is developing the next generation oral substrate re...
Back to Newsroom